Ruxolitinib as a Novel Therapeutic Option for Poor Prognosis T-LBL Pediatric Patients

Ruxolitinib as a Novel Therapeutic Option for Poor Prognosis T-LBL Pediatric Patients

Lymphoblastic lymphoma (LBL) is the second most common type of non-Hodgkin lymphoma in childhood, mainly of T cell origin (T-LBL). Although current treatment protocols allow a complete remission in 85% of cases, the second-line treatment overall survival for patients with progressive or relapsed dis...

Full description

Bibliographic Details
Main Authors: Giulia Veltri, Chiara Silvestri, Ilaria Gallingani, Max Sandei, Sara Vencato, Federica Lovisa, Giuliana Cortese, Marta Pillon, Elisa Carraro, Silvia Bresolin, Alessandra Biffi, Giuseppe Basso, Benedetta Accordi, Lara Mussolin, Valentina Serafin
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
T-LBL
ruxolitinib
Jak2
resistance
Online Access:https://www.mdpi.com/2072-6694/13/15/3724

Internet

https://www.mdpi.com/2072-6694/13/15/3724

Similar Items